/ 2 items

#TRVI↓

TRVI/ 07/21/2026 · 1:18 PM

BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough

BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.

TRVI/ 03/09/2026 · 3:33 PM

FDA Clears Path for Haduvio, But Trevi’s “Safe” Two-Trial Plan Sends TRVI Down

Trevi Therapeutics shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program.